Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Paclitaxel and novel methoxyphthalazinone BTK (Bruton's Tyrosine Kinase) inhibitor combined medicinal composition and application thereof

A technology of methoxyphthalazinone and inhibitors, which can be used in drug combinations, antineoplastic drugs, and pharmaceutical formulations, and can solve problems such as drug resistance, multiple side effects, and unsatisfactory selectivity.

Inactive Publication Date: 2019-03-19
NANJING ADVANCED BIOLOGICAL MATERIALS & PROCESS EQUIP INST CO LTD
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] It is currently known that the selectivity of BTK inhibitors is not ideal. In addition to inhibiting BTK, it also inhibits various other kinases (such as ETK, EGF, BLK, FGR, HCK, YES, BRK and JAK3, etc.), resulting in more side effects; at the same time , BTK binding site mutations often lead to drug resistance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Paclitaxel and novel methoxyphthalazinone BTK (Bruton's Tyrosine Kinase) inhibitor combined medicinal composition and application thereof
  • Paclitaxel and novel methoxyphthalazinone BTK (Bruton's Tyrosine Kinase) inhibitor combined medicinal composition and application thereof
  • Paclitaxel and novel methoxyphthalazinone BTK (Bruton's Tyrosine Kinase) inhibitor combined medicinal composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 Preparation of 8-methoxy-2H-phthalazin-1-one

[0028]

[0029] Step 1: Weigh 3-methoxy-1-dimethoxymethylbenzene (500mmol) into a reaction flask, add tetrahydrofuran (800ml) to dissolve, add s-BuLi (565mmol) under nitrogen protection at 60°C, The reaction was stirred at -60 °C for 1 h.

[0030] Step 2: Weigh dry ice (50mmol) into a reaction flask, add tetrahydrofuran (200ml), add n-BuLi (5ml), stir for 2h under nitrogen protection, add the mixture of step 1, continue stirring for 30min, stop the reaction, add water 1000ml, adjust the pH to 2 with concentrated hydrochloric acid, separate the organic phase, extract the aqueous phase with ethyl acetate, combine the organic phases, wash with saturated brine, dry over anhydrous sodium sulfate, and recrystallize to obtain 3-methoxy-2-dimethyl Oxymethylbenzoic acid.

[0031] Step 3: Weigh the product obtained in Step 2 (400mmol), acetic acid (93mmol), and hydrazine (600mmol) into a reaction flask, add 300ml of is...

Embodiment 2

[0033] Example 2 Preparation of (3,4-dihydroisoquinoline-2(1H)-formic acid tert-butyl ester-5-yl)-carbamic acid p-chlorobenzyl ester

[0034]

[0035] Weigh triphosgene (5mmol) into a reaction bottle, add 100ml of toluene, add dropwise 20ml of tetrahydrofuran solution dissolved with p-chlorophenol (5mmol) and pyridine (10ml) at 0°C, after the drop is completed, continue to react at room temperature for 8h, concentrate the reaction solution, added 40ml of dichloromethane, suspended to dryness, and obtained p-chlorobenzyl chloroformate, which was directly used in the next step.

[0036]Weigh 5-amino-3,4-dihydroisoquinoline-2(1H)-tert-butyl carboxylate (50mmol) and DIPEA (100mmol) into a reaction flask, add 300ml of dichloromethane, and slowly add it dropwise under stirring at room temperature p-chlorobenzyl chloroformate (51mmol), after dropping, continue to stir at room temperature for 1h, stop the reaction, concentrate the reaction mixture, add 70ml of ethyl acetate, wash w...

Embodiment 3

[0038] Example 3 (3,4-dihydroisoquinoline-2(1H)-tert-butyl formate-5-yl)-carbamic acid-4-[8-methoxy-(2H)-phthalazine-1- Preparation of keto]benzyl ester

[0039]

[0040] Weigh 8-methoxy-2H-phthalazin-1-one and (3,4-dihydroisoquinoline-2(1H)-formic acid tert-butyl ester-5-yl)-carbamic acid p-chlorobenzyl ester ( 195mmol) in a reaction flask, add DMF100ml, react overnight at 55°C, stop the reaction, add 100ml of water, 200ml of dichloromethane, extract, separate the organic phase, continue to extract the aqueous phase with dichloromethane (3*50ml), combine the organic phase, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain the title compound.

[0041] ESI–MS:[M+H] + m / z 557.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a paclitaxel and novel methoxyphthalazinone BTK (Bruton's Tyrosine Kinase) inhibitor combined medicinal composition. The composition comprises active ingredients and pharmaceutically acceptable auxiliary materials; the active ingredients consist of paclitaxel and a BTK inhibitor as shown in the formula (I); and the paclitaxel and the BTK inhibitor as shown in the formula (I)of the active ingredients are in the molar ratio of (0.14 to 0.20) to 1. The medicinal composition can be used for preparing a medicament for preventing and / or treating BTK-related diseases; and thetreatment effect is good.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, and relates to phthalazinone BTK inhibitors and applications thereof, in particular to phthalazinone BTK inhibitors, a preparation method thereof, a pharmaceutical composition containing the compound, and its application in the treatment of Bruton casein Use in amino acid kinase-associated diseases. Background technique [0002] Bruton's tyrosine kinase (BTK) is a member of the Tec family. It consists of a unique N-terminal domain, namely PH (pleckstrin homology) domain, TH (Tec homology) homology region, SH3 (Srchomology3) domain, SH2 (Src homology2) domain and catalytic domain, also known as SH1 / TK (Srchomologyl / Tyrosine kinase) domain or kinase domain composition (Akinleye et al: Ibrutiniband novel BTK inhibitors in clinical development. Journal of Hematology & Oncology 2013, 6: 59). During the normal development of B lymphocytes, the correct expression of different protein regions of the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/502A61K31/337A61K31/454A61P35/00A61P35/02C07D401/12
CPCA61P35/00A61P35/02A61K31/337A61K31/454A61K31/502C07D401/12A61K2300/00
Inventor 郭程杰
Owner NANJING ADVANCED BIOLOGICAL MATERIALS & PROCESS EQUIP INST CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com